PERFORMANCE CHARACTERISTICS OF SNIBE SARS-COV-2 IgM/IgG AND SARS-COV-2 S-RBD IgG SEROLOGICAL ASSAYS
Keywords:
SARS-Cov-2, verification of the chemiluminescence immunoassay for SARS-Cov-2 IgM,/IgG and SARS-Cov-2 S-RBD IgG antibodies.Abstract
Since corona virus emerged, few tests for diagnosis and follow-up of the disease were approved for urgent use by FDA. Serological tests for the presence of SARS-Cov-2-specific M/G and RBD IgG antibodies manufactured by SNIBE were introduced to the market at the beginning of 2020, with a primary recommendation for monitoring and responding to SARS-Cov-2 infection or vaccines.
According to the Standard ISO 15189, each laboratory should take special actions before implementation of any new analyses as routine ones. Bearing this in mind, a verification of the chemiluminescence method for antibody detection according to the CLSI EP 15-A2 and CLSI EP 15-A3 protocol was done in our laboratory.
Pooled control samples for IgG, IgM and RBG IgG with two levels, as well as serum samples for positive IgG antibodies were used for method verification. As part of the verification procedure, the precision of the method was estimated.
The results of the repeatability and coefficients of variation for SARS-Cov-2 IgM/IgG and SARS-Cov-2 S-RBD IgG were equal or less than the manufacturer’s claims, except for negative control RBD IgG samples. Estimated results for within-laboratory precision (reproducibility) as well as coefficients of variation were less or equal to the manufacturer’s claims, except for positive control samples for IgM.
We can conclude that the estimated performance characteristics of SNIBE SARS-Cov-2 IgM/IgG and SARS-Cov-2 S-RBD IgG serological assays are consistent with the manufacturer’s claim’ and that they can be introduced in our laboratory.
References
Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/ antibody-tests-guidelines.html. Visited on February 25th 2022.
Gundlapalli AV, Reynolds MS, Brooks JT, et al. SARS-Cov-2 serologic assay needs for the next phase of U.S. COVID-19 pandemic response. Open forum Infect Dis 2020; 8: 555.
International Standards Organization. Medical laboratories-Requirements for quality and competence International Standard, ISO 15189, 3rd (ed); 2012.
Clinical and Laboratory Standards Institute. User verification of performance for precision and trueness; verification of performance for precision and trueness; approved guideline-second edition. CLSI document EP15-A2. Wayne PA, USA: CLSI: 2005.
Iglewicz B, Hoaglin DC. How to detect and handle outliers. ASQC Quality Press 1994; Wis: Milwaukee; 1993.
Chester D. Evaluating Assay Precision. Clin Biochem Rev 2008; 29(1): S23-6.
Yokoyama R, Kurano M, Morita Y, Takuya Sh, Yuki N, Chungen Q, et al. Validation of a new automated chemiluminescent anti-SARS-Cov-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan. PLOS ONE 2021; 1-16.
Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performance of a chemiluminescence immunoassay for SARS-Cov-2 IgM/IgG and antibody kinetics. Clinical Chemistry and Laboratory Medicine 2020; 58(7): 1081-1088.
Recipients fact sheets-MAGLUMI 2019-nCov IgG/M. Available from: www.fda.gov. Visited on March 20th 2022.
SNIBE-Maglumi SARS-CoV-2 S-RBD IgG II (CLIA). Available from: https://hea.lthcare-in-europe.com. Visited March 18th 2022.
